Thermo Fisher Scientific TMO continues to demonstrate
improved relative strength, albeit still shy of benchmark. The company has shown its depth with schedules to
present at the Morgan Stanley 22nd Annual Global Healthcare Conference and investor moves such as
Mirova US LLC raising stock positions and
HB Wealth Management LLC increasing stock holdings. Analysts have rated TMO a
moderate buy with its strong financial prospects and solid fundamentals in spite of declining stock. TMO has reported its
second quarter results and is set to hold an earnings conference call. The company's stock has been evaluated at
attractive valuations, recently increasing by 40% in five months. It has outperformed market expectations and demonstrated a steady
compound annual growth rate (CAGR) of 14% over the last five years. Highlights also included the
acquisition of Olink and the release of a
Corporate Social Responsibility Report. Despite warnings about demand in 2024, the robust financial status of TMO keeps investors' interest high.
Thermo Fisher Scientific TMO News Analytics from Wed, 31 Jan 2024 08:00:00 GMT to Sun, 01 Sep 2024 11:21:33 GMT -
Information 6
- Rumor -2
